2020
DOI: 10.15789/2220-7619-aea-1458
|View full text |Cite
|
Sign up to set email alerts
|

An early assessment of the efficacy of medicines in the treatment of patients with COVID-19

Abstract: Резюме. Коронавирусная инфекция 2019 года является современным вызовом мировому сообществу. На фоне отсутствия вакцин эффективные и безопасные лекарства являются ургентным запросом системы здравоохранения. Нами была проведена оценка медицинских технологий, изучаемых при COVID-19. Поиск проводили с помощью международного ресурса СlinicalTrials.gov на начало апреля 2020 года. В результате было показано, что количество новых клинических исследований в мире, посвященных COVID-19, увеличивается на 65% в неделю. Чащ… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
1
0
2

Year Published

2020
2020
2022
2022

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(4 citation statements)
references
References 27 publications
1
1
0
2
Order By: Relevance
“…We believe that taking a drug in preventive doses does not exclude the possibility of infection with SARS-CoV-2, but against its background, there is an earlier recovery and smoothness of clinical symptoms, probably due to the antiinflammatory properties of the drug. The results obtained correspond to the data of the literature sources [6,7]. Thus, the risk group for occupational infection was dominated by middleaged women from among secondary and junior medical personnel with an appropriate level of education and, probably, the level of perception of new information associated with education.…”
Section: Resultssupporting
confidence: 84%
“…We believe that taking a drug in preventive doses does not exclude the possibility of infection with SARS-CoV-2, but against its background, there is an earlier recovery and smoothness of clinical symptoms, probably due to the antiinflammatory properties of the drug. The results obtained correspond to the data of the literature sources [6,7]. Thus, the risk group for occupational infection was dominated by middleaged women from among secondary and junior medical personnel with an appropriate level of education and, probably, the level of perception of new information associated with education.…”
Section: Resultssupporting
confidence: 84%
“…Важность РКИ для современной медицины сложно переоценить. Даже в неблагоприятных эпидемиологических условиях распространения вируса SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus), для поиска новых эффективных препаратов проводятся РКИ [43][44][45][46][47]. Одним из важных аспектов при проведении РКИ является выбор КТ.…”
Section: заключениеunclassified
“…"Protease inhibitor: lopinavir/ritonavir is one of the first drugs to be recommended for the treatment of COVID-19" [7, p. 16-17] Protease inhibitors include darunavir, which has at least been studied in only one (2020 data) clinical trial on an in vivo model. [6,8].…”
Section: Protease Inhibitors: Lopinavir / Ritonavir Darunavir and Dan...mentioning
confidence: 99%